Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier:
NCT00769236
First received: October 8, 2008
Last updated: August 27, 2014
Last verified: August 2014
  Purpose

We propose to study the intestinal secretion of ASCA by evaluating them in biopsy culture supernatants from a cohort of patients suffering from CD (n=80) and a cohort of control patients (UC (n=40) and patients without IBD (n=40 )).


Condition Intervention
Crohn's Disease
Other: Blood sampling and biopsy
Other: Biopsy and blood sampling

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease

Resource links provided by NLM:


Further study details as provided by Assistance Publique Hopitaux De Marseille:

Primary Outcome Measures:
  • Compare the performances of the dosage of the ASCA in floating it of culture of intestinal biopsies in that of their dosage in the serum [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine if the patients reached by disease of crohn not presenting ASCA in their serum represent one under group of disease of crohn [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Enrollment: 160
Study Start Date: June 2008
Study Completion Date: August 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1
Patients with crohn disease
Other: Blood sampling and biopsy
Biopsy and blood : Research for various antibodies
2
Patients reached by hemorrhagic first side-colitis
Other: Biopsy and blood sampling
Biopsy and blood : research for various antibodies
3
Patients controls
Other: Biopsy and blood sampling
Blood and biopsy : research for various antibodies

Detailed Description:

Its diagnosis is based upon clinical, endoscopic and histological parameters but recent studies have shown that seric evaluation of immunological markers (anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil cytoplasmic auti-antibodies (ANCA)) could be useful. Crohn's disease (CD) is an inflammatory bowel disease (IBD) of the young people. Antibodies anti-chitobisoside carbohydrate (ACCA), anti-laminaribioside carbohydrate (ALCA) and anti-mannobioside carbohydrate (AMCA) have been described as new serological markers of CD.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients reached by disease of crohn
  • patients reached by hemorrhagic first side-colitis

Exclusion Criteria:

  • Forms ileales or ano-périneales pure of disease of crohn
  • indefinite colitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00769236

Locations
France
Laboratoire d'Immunologie - Hopital de la Conception
Marseille, France, 13005
Sponsors and Collaborators
Assistance Publique Hopitaux De Marseille
Investigators
Principal Investigator: Sophie Desplat-Jego, MD Assistance Publique des Hopitaux de Marseille
  More Information

No publications provided

Responsible Party: Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier: NCT00769236     History of Changes
Other Study ID Numbers: 2008-A00080-55, 2008-05
Study First Received: October 8, 2008
Last Updated: August 27, 2014
Health Authority: France: Ministry of Health

Additional relevant MeSH terms:
Crohn Disease
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Antibodies
Autoantibodies
Immunoglobulins
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 21, 2014